摘要
目的探讨不同剂量瑞舒伐他汀钙对脑梗死合并高脂血症患者血脂水平、血管内皮功能及神经功能的影响。方法选择2018年1月至2018年12月黄河三门峡医院收治的220例脑梗死合并高脂血症患者为研究对象,所有患者给予瑞舒伐他汀钙治疗,根据瑞舒伐他汀钙使用剂量将患者分为A组(n=117)和B组(n=103)。A组患者给予瑞舒伐他汀钙10 mg,口服,每日1次;B组患者给予瑞舒伐他汀钙20 mg,口服,每日1次;疗程均为1个月。对2组患者治疗前和治疗后血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血管内皮细胞生长因子(VEGF)、内皮素-1(ET-1)、一氧化氮(NO)水平进行比较;治疗前和治疗后,采用美国国立卫生研究院卒中量表(NIHSS)评估患者神经功能缺损情况,采用Barthel指数(BI)评估患者生活活动能力;治疗1个月后评估患者临床疗效;观察治疗期间患者不良反应发生情况。结果治疗前2组患者血清TC、TG、HDL-C、LDL-C水平比较差异均无统计学意义(P>0.05);与治疗前比较,治疗后2组患者血清TC、TG、LDL-C水平显著降低,血清HDL-C水平显著升高(P<0.05);治疗后,B组患者血清TC、TG、LDL-C水平显著低于A组,血清HDL-C水平显著高于A组(P<0.05)。治疗前2组患者血清VEGF、ET-1、NO水平比较差异均无统计学意义(P>0.05);与治疗前比较,治疗后2组患者血清VEGF、NO水平显著升高,血清ET-1水平显著降低(P<0.05);治疗后,B组患者血清VEGF、NO水平显著高于A组,血清ET-1水平低于A组(P<0.05)。治疗前2组患者NIHSS评分、BI评分比较差异均无统计学意义(P>0.05);与治疗前比较,治疗后2组患者NIHSS评分显著降低,BI评分显著升高(P<0.05);治疗后,B组患者NIHSS评分显著低于A组,BI评分显著高于A组(P<0.05)。A组和B组患者治疗总有效率分别为86.32%(101/117)、95.14%(98/103),B组患者总有效率显著高于A组(χ^(2)=3.967,P<0.05)。A组和B�
Objective To investigate the effect of different doses of rosuvastatin calcium on blood lipid levels,vascular endothelial function and neurological function of patients with cerebral infarction and hyperlipidemia.Methods A total of 220 patients with cerebral infarction and hyperlipidemia admitted to Huanghe Sanmenxia Hospital from January 2018 to December 2018 were selected as the research subjects.All patients were treated with rosuvastatin calcium,and the patients were divided into group A(n=117)and group B(n=103)according to the dosage of rosuvastatin calcium.The patients in the group A were treated with 10 mg rosuvastatin calcium,while the patients in the group B were treated with rosuvastatin calcium 20 mg by oral,once a day for one month.The levels of serum total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),vascular endothelial growth factor(VEGF),endothelin-1(ET-1)and nitric oxide(NO)were compared between the two groups before and after treatment.Before and after treatment,the neurologic impairment of patients was evaluated by the National Institutes of Health Stroke Scale(NIHSS),and the activity of life was evaluated by Barthel index(BI).The adverse reactions of patients were observed during the treatment,and the clinical efficacy was evaluated after one month of treatment.Results There was no significant difference in serum TC,TG,HDL-C and LDL-C levels between the two groups before treatment(P>0.05).Compared with before treatment,the levels of serum TC,TG and LDL-C after treatment were significantly decreased,while the level of serum HDL-C after treatment was significantly increased in the two groups(P<0.05).After treatment,the levels of serum TC,TG and LDL-C in the group B were significantly lower than those in the group A,and the level of serum HDL-C in the group B was significantly higher than that in the group A(P<0.05).There was no significant difference in serum VEGF,ET-1 and NO levels between the two groups before treatment
作者
刘成
LIU Cheng(Department of Neurology,Huanghe Sanmenxia Hospital,Sanmenxia 472000,Henan Province,China)
出处
《新乡医学院学报》
CAS
2021年第5期453-457,共5页
Journal of Xinxiang Medical University
关键词
瑞舒伐他汀钙
脑梗死
高脂血症
血脂
血管内皮功能
神经功能缺损
rosuvastatin calcium
cerebral infarction
hyperlipidemia
blood lipid
vascular endothelial function
neurologic impairment
